Zacks.com Quotes and Research

ANADYS PHARMACEUTICALS INC (NASD)
ANDS 2.19 N/A (N/A%) Vol.  0 N/A ET

Day Low - High N/A - N/A
52wk Low - High 1.44 - 8.43
Avg Volume 329,944
Industry MED-BIOMED/GENE
Market Cap 81.71 M
Div - Yield 0.00 - 0.00
PE (forward)
PEG Ratio N/A
Current Year Est. -.86
EPS Last Year -1.02
Detailed Quote


Premium Research: Stock Analysis

Zacks Rank

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
#1 Strong Buy 26.51%
#2 Buy 16.63%
#3 Hold 7.53%
#4 Sell 2.01%
#5 Strong Sell -0.07%
S&P 500 8.70%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


upgraded 10/31/2009
Short-Term Rating 1-3 Months
PREMIUM
Zacks Recommendation

Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.

The Zacks Recommendations are split into 3 groups: Outperform, Neutral and Underperform. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock. More on these reports below.

Difference Between Zacks Rank and Zacks Recommendation
Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations


Long-Term Rating 6+ Months
PREMIUM
Zacks Industry Rank

Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.

When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

About Zacks Industry Rank
Zacks Industry Rank - All current industry ranks.
Zacks Premium - The only way to get access to the Zacks Industry Rank

PREMIUM
Target Price

The Zacks Price Target provides you our expectation for a stocks share price in the next 6 months. These price targets are created by the Zacks Equity Research group to coincide with their recommendations that are also based on a 6 month time horizon.

Zacks Equity Research Home
Zacks Premium - The only way to get access to the Zacks Price Targets

PREMIUM
Equity Research Report

The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

Zacks Equity Research Home Zacks Premium - The only way to get access to Zacks Recommendations


Updated as of 11/10/2009
PREMIUM
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium

Premium Research: Industry Analysis

Top Peers Ticker Zacks Rank
ANADYS PHARMACEUTICALS INC ANDS PREMIUM
KERYX BIOPHARMA KERX PREMIUM
PROMETIC LIFE T.PLI PREMIUM
OREXIGEN THERAP OREX PREMIUM
See all MED-BIOMED/GENE Peers

BROKERAGE RECOMMENDATIONS
Current ABR 1.40
ABR (Last Week) N/A
# of Recs in ABR 15
Average Target Price 4.71
Industry Rank by ABR 49 out of 217
Rank in Industry 59 out of 172
More Brokerage Recommendations

Zacks Community PeopleAndPicks.com
Community Rating

PeopleAndPicks.com Community Stock Ratings

Rating Recommendation % of Stocks
5 stars Strong Buy 10%
4 stars Buy 20%
3 stars Hold 40%
2 stars Sell 20%
1 stars Strong Sell 10%
0 stars Not Rated  

We believe that a community of investors working together can create a superior stock rating system. Some call this "collective intelligence". Or simply...together we can beat the market!

A stock's Community Rating is calculated based on the aggregate input of the PeopleAndPicks Community. The proportion of buy to sell ratings, recency of analysis, and the average score of the users who rate it favorably all factor into a score of one to five stars.


How do you rate ANDS?
Buy
Sell
Find out what the Zacks Community
thinks of ANDS at PeopleAndPicks.com

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

 Interactive Java Charting
 Comparative Chart



 
ZACKS COMMENTARY FOR ANDS
Zacks Equity Research: Report for ANDS
Nov 10, 2009
Zacks Blog: Mid-Stage Study for Anadys Drug
Sep 25, 2009
Zacks Blog: Anadys Begins Mid-Stage Trial
Sep 11, 2009
Zacks Blog: Anadys Reports Narrower Loss
Jul 31, 2009
Zacks Blog: Earnings Preview: Anadys
Jul 22, 2009
More Zacks Commentary
NEWS
Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference
Nov 24, 2009
Anadys Pharma (ANDS) Upgrade Alert, Watch for 8.5% Technical Downtrend Reversal
Nov 03, 2009
Analyst Upgrades for November 3rd
Nov 03, 2009
Anadys Pharmaceuticals Down 7% Since SmarTrend's Sell Recommendation
Nov 02, 2009
Anadys Pharmaceuticals Reports Third Quarter 2009 Financial Results and Program Highlights
Oct 29, 2009
More News
EARNINGS ESTIMATES
  This Quarter
12/2009
Next Quarter
03/2010
This Year
12/2009
Next Year
12/2010
Average Estimate -0.17 -0.22 -0.86 -0.68
Number of Estimates 12 5 12 12
Low Estimates -0.24 -0.39 -0.95 -1.54
High Estimate -0.10 -0.14 -0.79 -0.18
Year Ago EPS -0.30 -0.30 -1.13 -0.86
EPS Growth 43.06% 26.67% 23.75% 20.79%

More Estimates

COMPANY DESCRIPTION
Anadys Pharmaceuticals, Inc., is a biopharmaceutical company committed to advancing patient care by discovering, developing and commercializing novel small molecule medicines for the treatment of viral diseases and cancer. The Company's programs focus on Toll-Like Receptor-based small molecule product candidates and direct antiviral compounds that inhibit key steps in viral proliferation. The Company has core expertise in medicinal chemistry coupled with structure-based drug design, and is developing compounds for the treatment of hepatitis C infection, hepatitis B infection and cancer.

Full Company Report
FINANCIALS
EPS TTM -1.02
Sales 24.12
Net Income -31.54
Price/Earnings N/A
Price/Book 4.47
Price/Cash Flow N/A
Price/Sales N/A


More Financials